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Effects of erythropoietin therapy on the lipid profile in end.stage renal
failure. To evaluate the effects of erythropoietin (EPO) therapy on the
lipid profile in end-stage renal failure, we undertook a prospective study
in patients on both hemodialysis (HD) and continuous ambulatory
peritoneal dialysis (CAPD). One hundred and twelve patients (81 HD,
31 CAPD) were enrolled into the study. Lipid parameters [that is, total
cholesterol and the LDL and HDL subfractions, triglycerides, lipopro-
tein (a), apoproteins A and B], full blood count, iron studies, Bl2,
folate, blood urea, aluminium and serum parathyroid hormone were
measured prior to commencement of EPO therapy. Ninety-five patients
were reassessed 5.2 0.3 (mean SEM) months later and 53 patients
underwent a further assessment 13.1 0.6 months after the commence-
ment of EPO, giving an overall follow-up of 10.0 0.6 months in 95
patients. As expected, EPO treatment was associated with an increase
in hemoglobin (7.7 0.1 vs. 9.9 0.2 g/dl; P < 0.001) and a decrease
in ferritin (687 99 vs. 399 69 pg/liter; P < 0.01). A significant fall in
total cholesterol occurred (5.8 0.1 vs. 5.4 0.2 mmollliter; P < 0.05)
in association with a fall in apoprotein B (1.15 0.04 vs. 1.04 0.06;
P <0.05) and serum triglycerides (2.26 0.14 vs. 1.99 0.21; P <0.05)
during the course of the study. Other lipid parameters did not change,
although there was a trend towards improvement. These changes
correlated with the increase in Hb (P < 0.001 in each case), and the
reduction in ferritin for total cholesterol (P < 0.02), LDL cholesterol (P
<0.03), and to a lesser extent apoprotein B (P < 0.07). No difference
was observed in patients using maintenance HD or CAPD, and similar
trends were observed in male and female patients. Improvements in the
lipid profile occurred independently of the time on dialysis prior to the
commencement of EPO. We conclude that EPO treatment is associated
with alterations in the lipid profile which may suggest a long-term
improvement in the vascular morbidity of chronic renal failure. The
causes of the improved lipids are not addressed by this study and may
be equally due to a direct or secondary benefit of EPO therapy.
Erythropoietin (EPO) deficiency is an undoubted factor in the
pathogenesis of uremic anemia, and its widespread use has
arguably been the most important development impacting on
dialysis patients in recent years. However, the long-term effects
of erythropoietin on cardiovascular disease have not yet been
assessed. In particular, the effect of EPO on the blood lipid
profile has not been well documented.
There are theoretical benefits resulting from the use of EPO
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on cardiovascular disease in uremia. The resultant increase in
hemoglobin causes improved tissue oxygenation, not only to
the heart, but also to the vascular endothelium. Increased
exercise tolerance is well documented [I] to improve the
cardiovascular risk profile in nonuremic patients. An improve-
ment in the known carbohydrate intolerance of uremia has also
been demonstrated [2].
Conversely, there are also potentially adverse effects of EPO
treatment on cardiovascular risk factors. An increase in hemo-
globin leads to an increase in blood viscosity, hypertension may
be exacerbated and increased appetite may lead to weight gain
[1]. Thus an alteration in metabolic conditions may occur as a
result of EPO treatment which may theoretically be beneficial,
or conversely, adversely affect the lipid profile. The net effect of
these changes is not well documented. The current study
prospectively assessed the changes in the blood profile which
occurred in association with EPO treatment in patients on
long-term dialysis.
Methods
The study included patients from three dialysis units in
Sydney, Australia. All patients on hemodialysis, which in-
cluded both single pass and sorbent dialysis, and patients on
CAPD who were commencing erythropoietin treatment were
enrolled into the prospective study. Patients prescribed phar-
macological lipid lowering agents were excluded from the study
from the time these agents were commenced. Dialytic prescrip-
tion, EPO doses and other drug therapy was at the discretion of
the primary care physician. Attempts were made to keep
dialytic regimens uniform throughout the study unless clinical
considerations dictated otherwise. Hemodialysis patients were
dialyzed using cupraphan or cellulose acetate membranes
which were not altered during the course of the study. Kinetic
modeling was not routinely used to monitor dialysis delivery.
Patients on CAPD used standard peritoneal dialysate (Dianeal,
Baxter Healthcare, Round Lake, Illinois, USA). No patient on
CAPD required a significant variation in the dialysate glucose
content, nor in dialysate volume instilled during the study
period. All patients were similarly advised by a dietician
regarding a diet appropriate to their dialysis and low in satu-
rated fats.
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Assessments were made prior to the commencement of EPO,
at three to six months (follow-up 1) and 12 to 18 months
(follow-up 2) after EPO treatment was started. Measurements
included hemoglobin and hematocrit; pre-dialysis blood urea;
iron status as determined by serum iron and ferritin; serum B12
and folate; as well as factors known to be associated with EPO
resistance, that is, serum parathyroid hormone and aluminum
levels. The lipoprotein profile was assessed by measuring the
following parameters: total cholesterol, LDL cholesterol, HDL
cholesterol, triglycerides, apoproteins Al and B, and lipopro-
tein (a). All lipid measurements were performed in a single
laboratory. Other measurements were standard laboratory pro-
cedures and performed in individual laboratories.
Total cholesterol was measured by a spectrophotometric
colorimetric end-point determination using the Boehringer
Mannheim Enzymic Method run on the Hitachi 705 analyzer.
HDL cholesterol was measured using the Seba Diagnostics kit
which employs polyethylene glycol as the precipitant. LDL was
directly measured by subtracting the HDL cholesterol from the
cholesterol content of the lowermost fraction following ultra-
centrifugation at 100,000 g for 24 hours. Triglycerides were
determined by Boehringer Mannheim GPO-PAP method on the
Hitachi 705 analyzer. Apoproteins were measured by nephe-
lometry using the Beckman nephelometer, with the apoprotein
B assay specific for apoprotein B 100. Lipoprotein (a) was
measured by radioimmunoassay using a Pharmacia kit.
Due to ethical considerations, a control group of patients with
a similar degree of anemia not treated with EPO was not
available for comparison on a prospective basis. Thus, in order
to determine whether increased time on dialysis per Se was
associated with alterations in the lipid profile, patients in whom
EPO was commenced within one year of the commencement of
dialysis were compared with those who had been on mainte-
nance dialysis for greater than one year.
Statistical analysis
Statistical analyses were made using Statview Il® software.
Longitudinal changes in measured parameters were compared
using paired t-tests. Comparisons between two groups were
made using unpaired t-tests or chi-squared statistics. Analysis
of variance was used to detect differences between three
groups, and the protected Fisher test for least significant
difference was used to determine which pairs of groups differed
when the F test was significant. Correlations were sought
between the changes in lipoproteins, that is, total serum cho-
lesterol, triglycerides, HDL and LDL cholesterol, apoproteins
Al and B and lipoprotein (a), and the changes in hematological
and biochemical parameters using univariate and multivariate
analysis. A P value less than 0.05 was considered a significant
difference.
Results
A total of 112 patients (57 males and 55 females) were entered
into the study. The ages reflected the populations of the
hospitals involved in the study and ranged from 18 to 85 years
(59.9 1.4 years; mean sEM). Males and female patients
were similarly aged being 59.2 2.1 versus 60.9 1.9 years
respectively. Eighty-one patients were on maintenance hemo-
dialysis, with 32 patients on single pass and 49 on sorbent
dialysis. No difference was observed between patients who
used either form of hemodialysis, and no center effect was
evident. Thus the hemodialysis group was regarded as uniform.
Thirty-one patients were on continuous ambulatory peritoneal
dialysis (CAPD).
The primary causes of end-stage renal failure were: primary
glomerulonephritis 36.6%; analgesic nephropathy 21.4%; diabe-
tes mellitus 8%; unclassified 7.5%; chronic interstitial nephritis
4.5%; renovascular 3.6%, hypertension 3.6%; reflux nephropa-
thy 3.6%; polycystic kidneys 2.7%; multiple myeloma 2.7%,
amyloid 2.7%, other 3.1%. This reflects the study population at
the study centers, but differs from the Australian experience in
general, where analgesic nephropathy accounts for 11% and
diabetic nephropathy for 14% of the end-stage renal failure
population [3].
Those on hemodialysis and CAPD were aged similarly, being
59.5 1.75 versus 61.2 2.4 years, respectively, and had been
on dialysis for a similar length of time 30.5 4.6 versus 28.7
6.7 months.
Patients were followed from 3 to 18 months from commence-
ment of the study. During this period 22 patients died, 5
underwent renal transplantation and 4 commenced pharmaco-
logical lipid lowering agents. The causes of death were: cere-
brovascular accident 4, myocardial infarction 5, withdrawal
from dialysis 4, malignancy 3, infection 3, pancreatitis 1,
accidental 1, and cardiac tamponade 1. The excess death rate is
accounted for by the high representation of patients with
analgesic nephropathy and the elderly in the study population.
Ninety-five patients completed at least one follow-up at 5.2
0.3 months, and 53 patients completed a second follow-up 13.1
0.6months after the initial assessment. Overall, the follow-up
in 95 patients was 10.0 0.6 months.
The hematological, biochemical and lipid results for the initial
and follow-up assessments are presented in Table 1. As ex-
pected the hemoglobin increased significantly in association
with decreased serum ferritin. Parathyroid hormone fell at the
second assessment, but showed no difference from baseline at
the time of the final measurement. No significant difference in
dialysis efficiency as measured by pre-dialysis urea was evident
during the course of the study. Serum albumin levels increased
by a small but significant amount following the introduction of
EPO, with the major effect evident at the time of first follow-up.
There was a trend for serum albumin to correlate with total
serum cholesterol in the initial assessment (r — 0.2; P = 0.06).
However, this association was not present at the final follow-up
(r 0.01; P = 0.96). No change in B12 or folate occurred as a
result of EPO treatment and, although serum aluminum levels
tended to increase, no significant change occurred during the
course of the study.
Fasting blood sugar levels were similar before and after the
instigation of EPO treatment. However, significant reductions
occurred in the total cholesterol and triglycerides. This fall in
total cholesterol was associated with a fall in apoprotein B.
Although LDL cholesterol fell significantly at the second fol-
low-up it was not significantly different from baseline at the final
assessment. A similar fall and subsequent return to baseline
was also evident in the blood sugar measurements. Otherwise,
the majority of any observed change was observed by the first
follow-up with little change evident in further follow-ups.
Overall, at the initiation of the study the prevalence of hyper-
cholesterolemia was 59% and of hypertriglyceridemia 47%.
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Table 1. Changes in measured parameters at baseline and during
follow-up in entire study population
Parameter
Baseline
(N = 112)
Follow-up 1(N = 95)
Follow-up 2(N = 58)
Hemoglogin g/dl
Hematocrit %
7.7 0.13
23.5 0.4
9.1 0.2c
27.1 0.7C
9.9 0.2
29.6 0.6
Urea inmol/liter 25.6 0.4 25.7 1.2 25.4 1.2
Iron p.nol/liter
Ferritin pg/liter
15.9 0.9
687 90.1
14.4 1.3
383 73b
14.7 1.3
99 69'
B12 pmollliter 432 42 395 75 421 37
Folate nmol/!iter 23.8 2.8 17.9 2.7 33.8 11.7
PTH ng/liter 240 31.1 113.5 5l 175 47.7
Aluminum 0.78 0.08 0.86 0.16 1.34 0.19
p,nol/liter
Albumin gld! 32.1 0.5 33.5 i.i 33.4 0.6C
Blood glucose 6.65 0.33 6.04 0.44a 6.23 0.62
mmol/liter
Total cholesterol 5.78 0.13 5.40 0.20a 5.38 0.2
mmol/liter
Triglycerides 2,26 0.14 2.07 0.10 1.99 0.21a
mmol/liter
HDL cholesterol 1.14 0.04 1.03 0.06 1.13 0.05
mmol/liter
LDL cholesterol 3.44 0.11 3.15 0.l9a 3.30 0.16
mmo!/ liter
Apo Al glliter 1,165 0.03 1.18 0.04 1,23 0.04
Apo B glliter 1.15 0.04 1.04 0.06a 1.04 0.o6
Lipoprotein (a) 806 76 579 90 531 63
mg/liter
a p < 0.05, b p < 0,01, ' P < 0.001 versus follow-up 1
d P < 0.05 versus follow-up 2
This high prevalence was significantly reduced to 42% (P <
0.001) and 42% (P < 0.05), respectively, following the introduc-
tion of EPO.
Lipoprotein (a) levels were elevated in all patient groups.
They were somewhat higher in patients on CAPD compared
with hemodialysis but the difference did not reach statistical
significance. A trend existed for a reduction in lipoprotein (a)
subsequent to the introduction of EPO (P = 0.16), but at the
final assessment it was similar to baseline. No correlation was
observed between Lp(a) and age, weight, hemoglobin, the
hematinic factors or predialysis urea. Although no correlation
was observed with total cholesterol (P = 0.17) or its subfrac-
tions, LDL cholesterol (P = 0.26) and HDL cholesterol (P =
0.12), there was a positive correlation with apoprotein A (P <
0.05). Thus, females tended to have a higher Lp(a) level
compared with males, but the overall difference was not signif-
icant (Table 3). No correlation was observed with apoprotein B
(P = 0.15) nor serum triglycerides (P = 0.14).
The differences in measured parameters between patients on
hemodialysis versus those on CAPD are detailed in Table 2, and
between male and female patients in Table 3. The baseline
results were as expected in that hemodialysis patients had a
lower blood sugar level and a higher serum aluminum compared
with patients on CAPD, and females had a higher cholesterol
which was accounted for by the HDL subfraction and its
associated apoprotein, apoprotein A. No difference in the effect
of EPO was seen in these subgroup compared to the study
population as a whole.
The changes in measured parameters between patients who
had been on dialysis for less than one year (N = 53; time on
dialysis 4 0.6 months) and the patients who had been on
Table 2. Changes in measured parameters at baseline and at each
individual's last follow up in hemodialysis and CAPD patients
Parameter
Baseline (N = 112) Final follow-up (N = 95)
Hemodialysis CAPD Hemodialysis CAPD
Hemoglogin 7.8 0.16 7.4 0.20 9.9 0.2 9.8 0.4
g/dl
Hematocrit % 23.9 0.5 22.3 0.7 29.7 0.73 29.2 1.4
Urea mmo!f 25.9 0.8 24.7 1.6 26.7 1.0 21.6 2.9
liter
Iron mol/ 16.4 1.1 14.3 1.7 15.3 1.7 13.1 1.8
liter
Ferritin g/ 701 114 650 138 365 82 483 132
liter
B12 pmol/liter 385 40 521 94 447 44 354 69
Folate nmol/ 23.5 3.8 24.5 3.5 41.5 16.3 15.4 45
liter
PTH ng/liter 248 37 221 58 150 60 231 79
Aluminum 0.89 0.1 0.54 0.06a 1.49 0.20 0.36 o.16
i.unol/!iter
Blood glucose 6.2 0.3 7.6 0.8a 5.3 0.3 8.7 1,9b
mmol/liter
Total 5.71 0.16 5.89 0.26 5.38 0.22 5.47 0.31
cholesterol
mmol/liter
Triglycerides 2.20 0.16 2.4 0.27 2.02 0.28 1.91 0.22
mmol/liter
HDL 1.16 0.05 1.09 0.06 1.14 0.06 1.09 0.06
cholesterol
mmol/liter
LDL 3.48 0.14 3.32 0.21 3.33 0.18 3.23 0.34
cholesterol
mmol/!iter
ApoAlg/!iter 1.18±0.03 1.13±0.04 1.28±0.05 1.20±0.05
Apo B glliter 1.12 0.04 1.23 0.09 1.04 0.06 1.04 0.13
Lipoprotein 731 76 936 157 516 164 599 32
(a) mg/liter
a p < 0.05, b p < 0.01 versus hemodialysis
dialysis for greater than one year (N = 59; time on dialysis 52.1
5.2 months) are shown in Table 4. These subgroups had a
similar degree of anemia at the commencement of the study and
a similar hematological response to EPO therapy. Initial iron
stores were lower in patients who had been on dialysis for a
shorter period of time, reflecting the transfusion requirements
of the dialysis patients prior to the introduction of EPO treat-
ment. The percent reduction in serum ferritin following EPO
treatment was similar. Somewhat suprisingly, the PTH levels
were similar in the groups and, although aluminum levels
tended to be lower in the patients on hemodialysis for a shorter
period, the differences failed to reach statistical significance.
No difference in total cholesterol, cholesterol subfractions or
triglycerides was observed either at baseline or at follow-up.
Apoprotein A levels were similar at baseline, however, were
higher in patients on dialysis for a shorter period at final
follow-up. Apoprotein B levels were similar at each time point
and lipoprotein (a) levels were similar in all groups.
Prior to the commencement of EPO, patients with a higher
hemoglobin had a lower serum cholesterol (r = 0.22;P < 0.05).
Univariate analysis demonstrated that the improvement in each
of the lipid parameters correlated with an increase in hemoglo-
bin (total serum cholesterol r 0.59; LDL cholesterol r = 0.51;
serum triglycerides r = 0.46; P < 0.001 in each case). A
correlation was also observed between the reduction in serum
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Table 3. Changes in measured parameters at baseline and at each
individual's last follow-up in male versus female patients
Parameter
Baseline (N = 112) Final follow-up (N = 95)
Male Female Male Female
Hemoglogin 7.8 0.16 7.7 1.9 10.1 0.4 9.6 0.3
g/dl
Hematocrit % 23.3 0.51 23.6 0.7 30.4 1.1 29.9 0.9
Urea mmol/ 27.1 1.2 24.2 1.1 25.6 1.3 25.6 1.4
liter
Iron imolI 15.4 1.2 16.3 1.4 17.5 2.2 15.7 3.4
liter
Ferritin p,gI 659 128 715 129 411 86 367 60
liter
Bl2pmollliter 448 63 415 58 420 67 413 71
Folate nmol/ 20.6 2.0 28.7 5.8 19.7 2.2 37.2 9.4
liter
PTH ng/liter 227 44 254 46 186 82 145 32
Aluminum 0.69 0.10 0.88 0.12 1.11 0.09 0.93 0.28
j.unol/ liter
Blood glucose 6.9 0.5 6.4 0.4 6.5 0.6 6.1 0.6
mmol/liter
Total 5.69 0.21 6.02 0.l7 5.54 0.41 5.27 0.38
cholesterol
mmol/liter
Triglycerides 2,21 0.20 2.31 0.19 2.18 0.49 1.78 0.23
mmol/liter
HDL 1.00 0.04 1.26 007b 1.02 0.06 1.14 0.07
cholesterol
mmol/liter
LDL 3.26 0.17 3.61 0.15 3.13 0.26 3.35 0.18
cholesterol
mmol/liter
Apo Al gluier 1.09 0,03 1.25 0.04c 1.20 0.07 1.32 0.07
ApoBg/liter 1.11±0.05 1.19±0.09 1.01±0.10 1.09±0.10
Lipoprotein 636 91 880 156 492 194 626 132
(a) mg/liter
a p < 0.05, b p < 0.01, P < 0.001 versus females
ferritin and total cholesterol (r = 0.44; P < 0.02), LDL
cholesterol (r = 0.44; P < 0.03) and to a lesser extent apopro-
tein B (r = 0.35; P < 0.07). Although there was a trend for the
fall in ferritin to correlate with the fall in triglycerides (r =0.28),
this failed to reach statistical significance (P =0.14). Multivari-
ate analysis was unable to demonstrate an effect of a decrease
in serum ferritin on lipids independent of the effect of an
increase in hemoglobin, although an independent trend existed
(P = 0.11 for total cholesterol and P = 0.13 for LDL choles-
terol).
Discussion
The present study demonstrates that EPO treatment in pa-
tients receiving long-term dialysis therapy is associated with an
improvement in the blood lipid profile. This is indicated by
significant reductions in total serum cholesterol, serum triglyc-
erides and the apoprotein B 100.
Although many studies have addressed the beneficial effects
of EPO treatment on cardiac disease, they mainly address the
improvement in ventricular function as a result of improved
tissue oxygenation [4, 5]. Due to its relatively recent introduc-
tion, the long-term benefits of reducing cardiac disease, which
is the major cause of death in our dialysis and transplant
population, are unknown. Few studies address the effects of
Table 4. Changes in measured parameters at baseline and at each
individual's last follow-up in patients on dialysis for greater than 12
months versus those on dialysis for less than 12 months
Baseline (N = 112) Final follow-up (N = 95)
>12 <12 >12 <12
Parameter months months months months
Hemoglogin 7.8 0.17 7.7 0.20 9.8 0.24 10.0 0.3
gIdi
Hematocnt % 23.5 0.3 23.6 0.7 29.3 0.10 29.8 0.9
Urea mmoll 24.7 1.0 27.0 1.2 24.2 1.5 27.2 1.8
liter
Iron jinol/ 19.1 1.2 11.1 0.9 15.3 2.4 14.2 1.5
liter
Ferritin g/ 856 123 544 72 381 111 293 52
liter
B12 pmollliter 425 54 443 69 410 56 435 48
Folate nmoll 24.4 4.3 22.9 2.3 35.5 21.8 31.8 5.4
liter
PTH ng/liter 257 43 210 39 189 56 127 96
Aluminium 0.88 0.1 0.6 0.11 1.63 0.28 0.9 0.14
pnol/liter
Blood glucose 6.7 0.4 6.7 0.5 6.3 0.8 6.2 0.9
mmol/liter
Total 5.8 0.18 5.8 0.20 5.3 0.29 5.5 0.26
cholesterol
mmol/liter
Triglycerides 2.4 0.19 2.11 0.23 1.86 0.15 2.1 0.44
mmol/liter
HDL 1.16 0.06 1.13 0.07 1.07 0.06 1,20 0.07
cholesterol
mmol/liter
LDL 3.45 0.15 3.50 0.18 3.22 0.22 3.40 0.23
cholesterol
mmol/liter
Apo Al g/liter 1.16 0.03 1.18 0.04 1.17 0.05 1.35 0.06k
Apo B g/liter 1.12 0.06 1.21 0.06 0.95 0.07 1.14 0.09
Lipoprotein 732 95 930 32 538 104 501 17!
(a) mg/liter
a p < 0.05, versus patients on dialysis greater than 12 months
EPO on the lipid profile, and these consist of few patients with
relatively limited follow-up.
Mat, Stolear and Georges [6] assessed 24 patients before and
9 to 36 months after EPO treatment and found no difference in
total cholesterol, HDL cholesterol, triglycerides, apoprotein Al
or apoprotein B. Similarly, Prata et al [7] studied 14 patients
before and after EPO treatment and showed no change in the
lipid profile. Conversely, Viron et al [8] cautiously proposed
that a favorable response in serum lipids may occur as a
response to EPO treatment in the dialysis patient, when they
documented an increase in the apoprotein Al. Our finding of a
decrease in total cholesterol from 5.8 to 5.4 is modest, and no
doubt the power of the above studies would not have allowed
detection of this difference. Nonetheless, in epidemiological
studies, a reduction in serum cholesterol of this magnitude is
associated with significant reductions in cardiovascular disease
[9, 10]. If one extrapolates from the "normal" population and
assumes a 1 to 2% decline in cardiovascular mortality with each
1% decline in cholesterol [10], then a decrease in coronary
mortality in the order of 10% could be expected from the results
of our study. Furthermore, a significant reduction in apoprotein
B was documented, which has been shown to associated with
regression of established coronary artery disease [11].
The reasons for this improvement are not elucidated fully by
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the present study. It may be that secondary lifestyle changes,
which were not assessed, with respect to exercise capacity and
diet are responsible for the observed benefits. However, other
metabolic effects of EPO may well be more directly responsible
for the observed changes. The carbohydrate intolerance of
uremia is known to improve following EPO treatment [2], and
an improvement in carbohydrate metabolism is known to be
associated with decreased serum triglycerides, as was observed
in this study. Normalization of several hypothalamic/pituitary
hormonal systems has been described after the use of EPO [12,
13], and these may secondarily improve the lipid profile.
The association between a reduction in total body iron stores
induced by EPO and an improved lipid proffle is interesting, as
there are several studies which suggest an association between
iron accumulation, blood lipid profiles and cardiovascular
death. Carbohydrate intolerance in itself is known to improve
when total body iron stores are lowered by phlebotomy [14, 15].
Cutler [16] demonstrated a similar improvement in glycemic
control when patients with an elevated serum ferritin had a
reduction in iron stores when treated with intravenous dexfor-
roxamine. In this small study of 16 patients, 15 had a reduction
in total cholesterol after treatment with desferroxamine, al-
though this failed to reach statistical significance probably due
to the small size of the study. Many studies have documented
the role of iron in accelerating atherogenesis and the relation-
ship between coronary artery disease and liver iron content [17,
18]. The effect of iron in accelerating coronary artery disease is
likely to be at least in part due to free radical production,
oxidative injury and lipid peroxidation. However, increased
iron stores have been demonstrated to aggravate the expression
of hyperlipidernia [19]. The current study suggests that a
reduction in body iron stores may have a positive effect in
improving the lipid profile. However, because of the strong
association between an increase in hemoglobin and a reduction
in iron stores, an independent effect could not be determined.
Indeed, the patients on dialysis for a shorter period of time had
a lesser degree of iron overload compared to those on dialysis
for a longer period despite a similar lipid profile. Thus, a
reduction in iron accumulation may be one of several mecha-
nisms whereby EPO positively affects serum lipids.
The absence of a comparable dialysis population who were
randomized not to receive EPO during the same time period
was unavoidable due to the ethical implications of witholding
EPO from patients in whom a beneficial effect would be
reasonably anticipated. Nonetheless, we do not consider that
the fall in lipids was likely to be due to factors other than the
instigation of EPO treatment. In the hemodialysis patients no
alteration in dialysis prescription occurred and no objective
evidence of altered dialysis delivery was observed. Similarly, in
the CAPD population no alteration in the dialysis regimen, and
in particular in the dialysate glucose content, occurred which
may have resulted in a improved lipid profile. As EPO is known
to stimulate appetite and pre-dialysis blood urea levels were
similar, a decrease in nutritional state was unlikely to account
for the observed reduction in lipid levels. Although the protein
catabolic rate was not routinely monitored in the study popu-
lation, it is further unlikely that progressive malnutrition ac-
counted for the fall in lipid parameters, as serum albumin rose
during the course of the study.
Importantly, patients who commenced EPO shortly after the
instigation of dialysis had a similar lipid profile at the baseline
assessment to those who had been on dialysis for a mean of 52
months. This suggests that a reduction in lipids with increasing
time on dialysis was not observed in the patients under study.
This is in agreement with most cross sectional and longitudinal
studies of patients on both hemodialysis and CAPD who have
shown no improvement in serum lipid and lipoproteins with
time on dialysis [20—22]. Indeed, some studies have demon-
strated that the lipid and lipoprotein profile of patients on
maintenance dialysis may in fact worsen with time [23, 24]. In
the current investigation the instigation of EPO was the only
parameter altered in overall patient treatment and is therefore
likely to be contributing either directly or indirectly to the
improvement in the lipid profile. It should be noted that the
study comprised few patients with diabetic nephropathy and the
results may not generalize to dialysis populations with a higher
proportion of diabetic patients.
Lipoprotein (a) has been implicated in the genesis of athero-
sclerosis [25], and the present study confirms that elevated
levels of Lp(a) occur in patients on dialysis [26]. Although no
correlation was observed between Lp(a) and LDL cholesterol
in the present study, previous investigators have found a
fivefold increase in atherogenic risk in patients with elevations
in both these lipid parameters [27]. The trend for a reduction in
these levels alter treatment with EPO points to a further
improvement in the patients overall atherogenic risk.
Thus, the study has demonstrated that an improvement in
total cholesterol, triglycerides and apoprotein B, which in the
method used in the current assay, is largely apoprotein BlOO
following EPO therapy. If the results of similar changes in lipid
profiles from epidemiological studies could be extrapolated to
the current study population, a reduction in vascular events
and, in particular, coronary artery disease is expected. The
reasons for the observed improvement are not explored in the
current study and may equally be of primary or secondary
benefit. However, the results provide optimism that the high
incidence of morbidity and mortality due to vascular events in
patients with end-stage renal failure may be reduced with EPO
treatment.
Reprint requests to Dr. C.A. Pollock, Department of Medicine, Royal
North Shore Hospital, NSW, 2065, Australia.
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